Newsroom

The ScaleReady team is going to be at Advanced Therapies week in Hosuton. We are eager to connect, explore innovations, and discuss strategies in cell and gene therapies. Visit us at our booth to further discuss the ScaleReady platform and all of our sponsored sessions at the conference.

Meet ScaleReady in Houston for the 39th Annual SITC Meeting in booth #927 alongside established leaders in the cancer immunotherapy field at this annual, information-filled conference. Our Field Application Specialists and G-Rex Optimization Specialists are looking forward to meeting with you on site!

With 23+ TIL expert speakers, 75% of which new, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp, this is an unrivalled opportunity to connect and collaborate with this niche community to secure clinical validation, turbocharge modified therapies and accelerate the next wave of TIL therapies into the clinic and beyond. Join us for our amazing presentation on October 23rd at 10am and at our booth!

The European Society of Gene and Cell Therapy has as its objective the promotion of science and research, join ScaleReady in 2024 in Rome at this exciting annual congress!

Save the dates for the upcoming Cell and Gene Meeting on the Mesa 2024 Conference from October 7th to 9th in Phoenix, Arizona. ScaleReady is sponsoring an extremely insightful Workshop Session and will be at our booth in the Exhibit Hall. Make sure you attend our session and meet with our team, we will see you there!

Join ScaleReady at the 8th Annual CAR TCR Summit in Boston, MA for the industry’s trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers.

ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.

Returning to Lisbon, Portugal, ScaleReady will be at the Advanced Therapies Europe 2024 Edition! Join our team to discuss the latest in cell and gene therapy manufacturing advances, and how the G-Rex bioreactor will simplify and streamline your processes ready for automation and scale. Make sure to join us for our in depth workshop discussion and our Plenary session hosted by the COO of CellReady, Ignacio Nunez. See you there!

ScaleReady is a proud Platinum Sponsor of the ISCT Europe 2024 Regional Meeting in Gothenburg Sweden from September 4th to 6th. We are excited to be hosting multiple speaking events such as our Tutorial Presentation at 12:30pm on September 4th and our Global Showcase Presentation at 10:15am on September 4th. Please visit our on-site team in booth #F02.04 to learn more about our events as well as our wide product portfolio!

The CGT sector is making significant strides, highlighted by the FDA approval of the first CRISPR therapeutic. Experts, including Josh Ludwig, Global Director, Commercial Operations, ScaleReady, predict continued growth and innovation in 2024 and beyond. Key challenges include manufacturing capacity, standardization, and delivery systems. However, advancements in technology and partnerships between developers and manufacturers offer promising solutions.

Bio-Techne, Wilson Wolf, and CellReady awarded a $300,000 G-Rex Grant to Stanford Medicine's LCGM for CAR-T cell therapy manufacturing. The grant is part of a $20 million initiative to support CGT development. Eligible recipients receive supplies, support, and discounts. Stanford Medicine LCGM plans to use the grant for a Phase I trial and potency testing. Feldman from Stanford Medicine LCGM expressed the grant's importance for future clinical trials. Wilson from Wilson Wolf praised Stanford University's reputation for innovation.

MaxCyte and ScaleReady have partnered for the G-Rex Grant Program, which aims to accelerate cell and gene therapy development. The program offers resources, tools, and expertise to recipients. MaxCyte's electroporation technology and ScaleReady's manufacturing solutions are key components of the program. The goal is to reduce barriers to entry for CGT companies and expedite the development of life-saving therapies.